{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:35:09Z","timestamp":1777268109257,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discovery"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the incidence of lung cancer has decreased due to the reduction of tobacco use, lung cancer remains the leading cause of cancer-related death. Lung squamous cell carcinoma represents 30% of lung cancers and only recently have possible drug-targetable mutations been identified in this disease, including fibroblast growth factor receptor 1 (FGFR1) gene amplification and genetic alterations in the phosphoinositide-3 kinase pathway. These discoveries have generated a great interest in the clinic and the initiation of clinical trials using FGFR tyrosine kinase inhibitors to treat FGFR-altered lung cancers. However, preliminary results from these studies have shown that not all patients respond to therapy. Here we review current unresolved questions on the selection of patients for their recruitment in FGFR tyrosine kinase inhibitor trials, how FGFR inhibitors could be combined with other targeted therapies or immunotherapies to improve patient outcome, and how the current preclinical models can help address these questions.<\/jats:p>","DOI":"10.1038\/cddiscovery.2015.49","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T16:22:42Z","timestamp":1448036562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies"],"prefix":"10.1038","volume":"1","author":[{"given":"CE","family":"Weeden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-L","family":"Asselin-Labat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"BFcddiscovery201549_CR1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104\u20131110.","journal-title":"Nat Genet"},{"key":"BFcddiscovery201549_CR2","first-page":"209ra153","volume":"5","author":"Clinical Lung Cancer Genome Project","year":"2013","unstructured":"Clinical Lung Cancer Genome Project . Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.","journal-title":"Sci Transl Med"},{"key":"BFcddiscovery201549_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"PS Hammerman","year":"2012","unstructured":"Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519\u2013525.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524: 47\u201353.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR5","doi-asserted-by":"publisher","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","volume":"2","author":"J Weiss","year":"2010","unstructured":"Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.","journal-title":"Sci Transl Med"},{"key":"BFcddiscovery201549_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ctrv.2015.04.011","volume":"41","author":"M Tiseo","year":"2015","unstructured":"Tiseo M, Gelsomino F, Alfieri R, Cavazzoni A, Bozzetti C, De Giorgi AM et al. FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treat Rev 2015; 41: 527\u2013539.","journal-title":"Cancer Treat Rev"},{"issue":"15_suppl","key":"BFcddiscovery201549_CR7","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/jco.2014.32.15_suppl.8034","volume":"32","author":"Lucia Nogova","year":"2014","unstructured":"Nogova L, Sequist LV, Cassier PA, Hidalgo M, Delord JP, Schuler MH et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol 2014; 32.","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"BFcddiscovery201549_CR8","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1200\/jco.2014.32.15_suppl.8035","volume":"32","author":"Paul K. Paik","year":"2014","unstructured":"Paik PK, Shen RL, Ferry D, Soria JC, Mathewson A, Kilgour E et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 2014; 32.","journal-title":"Journal of Clinical Oncology"},{"key":"BFcddiscovery201549_CR9","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from \u2018never smokers\u2019 and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306\u201313311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddiscovery201549_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947\u2013957.","journal-title":"N Engl J Med"},{"key":"BFcddiscovery201549_CR11","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167\u20132177.","journal-title":"N Engl J Med"},{"key":"BFcddiscovery201549_CR12","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","volume":"20","author":"MW Wynes","year":"2014","unstructured":"Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 2014; 20: 3299\u20133309.","journal-title":"Clin Cancer Res"},{"key":"BFcddiscovery201549_CR13","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1158\/1078-0432.CCR-12-2694","volume":"18","author":"J Zhang","year":"2012","unstructured":"Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 2012; 18: 6658\u20136667.","journal-title":"Clin Cancer Res"},{"key":"BFcddiscovery201549_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","volume":"2","author":"V Guagnano","year":"2012","unstructured":"Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 2: 1118\u20131133.","journal-title":"Cancer Discov"},{"key":"BFcddiscovery201549_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690\u2013699.","journal-title":"Mol Cancer Ther"},{"key":"BFcddiscovery201549_CR16","doi-asserted-by":"publisher","first-page":"e20351","DOI":"10.1371\/journal.pone.0020351","volume":"6","author":"A Dutt","year":"2011","unstructured":"Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.","journal-title":"PLoS One"},{"key":"BFcddiscovery201549_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/2159-8290.CD-13-0323","volume":"4","author":"F Malchers","year":"2014","unstructured":"Malchers F, Dietlein F, Schottle J, Lu X, Nogova L, Albus K et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov 2014; 4: 246\u2013257.","journal-title":"Cancer Discov"},{"key":"BFcddiscovery201549_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MCB.19.1.1","volume":"19","author":"CV Dang","year":"1999","unstructured":"Dang CV . c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1\u201311.","journal-title":"Mol Cell Biol"},{"key":"BFcddiscovery201549_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/JTO.0000000000000562","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X et al. Fibroblast growth factor receptor 1 and related ligands in small-cell lung cancer. J Thorac Oncol 2015; 10: 1083\u20131090.","journal-title":"J Thorac Oncol"},{"key":"BFcddiscovery201549_CR20","doi-asserted-by":"publisher","first-page":"e0135829","DOI":"10.1371\/journal.pone.0135829","volume":"10","author":"H Yan","year":"2015","unstructured":"Yan H, Li H, Li Q, Zhao P, Wang W, Cao B . The efficacy of synchronous combination of chemotherapy and EGFR TKIs for the first-line treatment of NSCLC: a systematic analysis. PLoS One 2015; 10: e0135829.","journal-title":"PLoS One"},{"key":"BFcddiscovery201549_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123\u2013135.","journal-title":"N Engl J Med"},{"key":"BFcddiscovery201549_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116\u2013129.","journal-title":"Nat Rev Cancer"},{"key":"BFcddiscovery201549_CR23","first-page":"S579","volume":"5","author":"P Savas","year":"2013","unstructured":"Savas P, Hughes B, Solomon B . Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013; 5: S579\u2013S592.","journal-title":"J Thorac Dis"},{"key":"BFcddiscovery201549_CR24","doi-asserted-by":"crossref","unstructured":"Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T et al. Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways as an effective strategy for treatment of lung cancer and HNSCC. Cancer Res 2015.","DOI":"10.1158\/0008-5472.CAN-15-0509"},{"key":"BFcddiscovery201549_CR25","doi-asserted-by":"publisher","first-page":"19503","DOI":"10.1073\/pnas.0905056106","volume":"106","author":"AC Faber","year":"2009","unstructured":"Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009; 106: 19503\u201319508.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddiscovery201549_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddiscovery201549_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","volume":"4","author":"MS Cragg","year":"2007","unstructured":"Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A . Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007; 4: 1681\u20131689, discussion 1690.","journal-title":"PLoS Med"},{"key":"BFcddiscovery201549_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899\u2013905.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR29","doi-asserted-by":"publisher","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015; 7: 279ra240.","journal-title":"Sci Transl Med"},{"key":"BFcddiscovery201549_CR30","doi-asserted-by":"publisher","first-page":"e1590","DOI":"10.1038\/cddis.2014.561","volume":"6","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.","journal-title":"Cell Death Dis"},{"key":"BFcddiscovery201549_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1021\/jm401948b","volume":"57","author":"RM Brady","year":"2014","unstructured":"Brady RM, Vom A, Roy MJ, Toovey N, Smith BJ, Moss RM et al. De-novo designed library of benzoylureas as inhibitors of BCL-XL: synthesis, structural and biochemical characterization. J Med Chem 2014; 57: 1323\u20131343.","journal-title":"J Med Chem"},{"key":"BFcddiscovery201549_CR32","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213\u20135219.","journal-title":"Cancer Res"},{"key":"BFcddiscovery201549_CR33","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","volume":"72","author":"RC Koya","year":"2012","unstructured":"Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72: 3928\u20133937.","journal-title":"Cancer Res"},{"key":"BFcddiscovery201549_CR34","doi-asserted-by":"publisher","first-page":"279ra241","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015; 7: 279ra241.","journal-title":"Sci Transl Med"},{"key":"BFcddiscovery201549_CR35","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355\u20131363.","journal-title":"Cancer Discov"},{"key":"BFcddiscovery201549_CR36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443\u20132454.","journal-title":"N Engl J Med"},{"key":"BFcddiscovery201549_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124\u2013128.","journal-title":"Science"},{"key":"BFcddiscovery201549_CR38","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189\u20132199.","journal-title":"N Engl J Med"},{"key":"BFcddiscovery201549_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00439-011-0990-0","volume":"130","author":"M Pajic","year":"2011","unstructured":"Pajic M, Scarlett CJ, Chang DK, Sutherland RL, Biankin AV . Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet 2011; 130: 93\u2013101.","journal-title":"Hum Genet"},{"key":"BFcddiscovery201549_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0523-1","volume":"17","author":"JR Whittle","year":"2015","unstructured":"Whittle JR, Lewis MT, Lindeman GJ, Visvader JE . Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 2015; 17: 17.","journal-title":"Breast Cancer Res"},{"key":"BFcddiscovery201549_CR41","first-page":"Unit14 23","volume":"Chapter 14","author":"YS DeRose","year":"2013","unstructured":"DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ et al. Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol 2013; Chapter 14: Unit14 23.","journal-title":"Curr Protoc Pharmacol"},{"key":"BFcddiscovery201549_CR42","doi-asserted-by":"publisher","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","volume":"112","author":"AC Faber","year":"2015","unstructured":"Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci USA 2015; 112: E1288\u2013E1296.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddiscovery201549_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cam4.357","volume":"4","author":"M Ilie","year":"2015","unstructured":"Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med 2015; 4: 201\u2013211.","journal-title":"Cancer Med"},{"key":"BFcddiscovery201549_CR44","doi-asserted-by":"publisher","first-page":"e106862","DOI":"10.1371\/journal.pone.0106862","volume":"9","author":"TL Leong","year":"2014","unstructured":"Leong TL, Marini KD, Rossello FJ, Jayasekara SN, Russell PA, Prodanovic Z et al. Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens. PLoS One 2014; 9: e106862.","journal-title":"PLoS One"},{"key":"BFcddiscovery201549_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2014.11.024","volume":"357","author":"C Hao","year":"2015","unstructured":"Hao C, Wang L, Peng S, Cao M, Li H, Hu J et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett 2015; 357: 179\u2013185.","journal-title":"Cancer Lett"},{"key":"BFcddiscovery201549_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13952","volume":"518","author":"P Eirew","year":"2015","unstructured":"Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015; 518: 422\u2013426.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR47","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nature09208","volume":"466","author":"Z Kan","year":"2010","unstructured":"Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869\u2013873.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR48","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","volume":"75","author":"JW Cassidy","year":"2015","unstructured":"Cassidy JW, Caldas C, Bruna A . Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res 2015; 75: 2963\u20132968.","journal-title":"Cancer Res"},{"key":"BFcddiscovery201549_CR49","doi-asserted-by":"publisher","first-page":"e0117417","DOI":"10.1371\/journal.pone.0117417","volume":"10","author":"Y Hiroshima","year":"2015","unstructured":"Hiroshima Y, Zhang Y, Zhang N, Maawy A, Mii S, Yamamoto M et al. Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One 2015; 10: e0117417.","journal-title":"PLoS One"},{"key":"BFcddiscovery201549_CR50","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","volume":"455","author":"L Ding","year":"2008","unstructured":"Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069\u20131075.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR51","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159: 440\u2013455.","journal-title":"Cell"},{"key":"BFcddiscovery201549_CR52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature13906","volume":"516","author":"FJ Sanchez-Rivera","year":"2014","unstructured":"Sanchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 2014; 516: 428\u2013431.","journal-title":"Nature"},{"key":"BFcddiscovery201549_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3950","volume":"15","author":"FJ Sanchez-Rivera","year":"2015","unstructured":"Sanchez-Rivera FJ, Jacks T . Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 2015; 15: 387\u2013395.","journal-title":"Nat Rev Cancer"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddiscovery201549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddiscovery201549","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddiscovery201549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T10:18:46Z","timestamp":1672913926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddiscovery201549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,21]]}},"alternative-id":["BFcddiscovery201549"],"URL":"https:\/\/doi.org\/10.1038\/cddiscovery.2015.49","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]},"assertion":[{"value":"15 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15049"}}